Policy Brief 6: The benefits of antiretroviral therapy for patients’ economic well-being

By  Professor Sydney Rosen  Bruce Larson  Julia Rohr  Professor Ian Sanne  Constance Mongwenyana  Alana T Brennan  Omar Galarraga  |  | 

Background

Large-scale provision of antiretroviral therapy (ART) for HIV/AIDS began in South Africa in 2004 and has scaled up steadily since then. A decade later, large numbers of patients are now reaching five, eight, or even more years on ART. The long-term biomedical outcomes of treatment have been well documented in South Africa, where antiretroviral provision has been associated with reductions in HIV-associated mortality and increases in life expectancy. Much less is known about the “non-biomedical” outcomes of treatment, in South Africa and elsewhere. A handful of studies have considered the implications of ART for quality of life, employment, and other economic and social indicators, but these studies have largely been limited to the one to two years after initiation of treatment. They have generally reported large improvements in the indicators they measured in the first 6-24 months after treatment initiation. In view of the lifelong commitment that ART requires, however, it is important to know whether these improvements persist, increase, or deteriorate in later years on treatment.

HERO Policy Brief 6-Benefits of ART-21 Oct 2013

Publication details

PDF